82905-1
Laboratoryt(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio] in Bone marrow by Molecular genetics method
Definition
The level of fusion gene transcript in the test sample is expressed as a log reduction; i.e., log10 of the ratio of chimeric BCR-ABL/normal ABL mRNA transcript seen in individuals with untreated CML (Chronic Myelogenous Leukemia) as compared to the ratio seen in the patient. In Quest's laboratory data, the median of BCR-ABL/ABL Ratio in previously untreated CML patients is 4.1325 in peripheral blood samples (N=120) and 5.09 in bone marrow samples (N=109). Based on the IRIS study (New England Journal of Medicine, 2003, 3349:1423-1432), it is not necessary to know the BCR-ABL:ABL ratio of a patient at baseline to calculate the subsequent change and this calculation should be based on the above-mentioned median. Based on this study, a 3 log of higher reduction by 12 months of therapy is associated with negligible risk of disease progression during the subsequent 12 months with patients are treated with imatinib. The following formula is used for calculating log reduction by Quest Laboratories: LOG10(4.1325)-LOG10 (BCR-ABL:ABL ratio) Unit/Log Reduction. Information from Quest Diagnostics. 2006 12 06.
LOINC 6-Axis Classification
Component
t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript
Property
LnRto
Time Aspect
Pt
System
Bone mar
Scale Type
Qn
Method Type
Molgen
Details
Class
MOLPATH.TRNLOC
Order/Observation
Both
Short Name
t(9;22)(ABL1,BCR)/control Mar-LnRto
Display Name
t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript Molgen (BM) [Log # ratio]
Related Names
Frequently Asked Questions
What is LOINC code 82905-1?
LOINC code 82905-1 identifies "t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio] in Bone marrow by Molecular genetics method". The level of fusion gene transcript in the test sample is expressed as a log reduction; i.e., log10 of the ratio of chimeric BCR-ABL/normal ABL mRNA transcript seen in individuals with untreated CML (Chronic Myelogenous Leukemia) as compared to the ratio seen in the patient. In Quest's laboratory data, the median of BCR-ABL/ABL Ratio in previously untreated CML patients is 4.1325 in peripheral blood samples (N=120) and 5.09 in bone marrow samples (N=109). Based on the IRIS study (New England Journal of Medicine, 2003, 3349:1423-1432), it is not necessary to know the BCR-ABL:ABL ratio of a patient at baseline to calculate the subsequent change and this calculation should be based on the above-mentioned median. Based on this study, a 3 log of higher reduction by 12 months of therapy is associated with negligible risk of disease progression during the subsequent 12 months with patients are treated with imatinib. The following formula is used for calculating log reduction by Quest Laboratories: LOG10(4.1325)-LOG10 (BCR-ABL:ABL ratio) Unit/Log Reduction. Information from Quest Diagnostics. 2006 12 06.
What does 82905-1 measure?
This code measures t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript in Bone mar. It belongs to the MOLPATH.TRNLOC class in the LOINC classification.
What is LOINC?
LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.